Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews

Executive Summary

The latest drug development news and highlights from our Performance Tracker.

Advertisement

Related Content

And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer
Keeping Track: An RMAT, Two QIDPs, And Some Bad News Too
Keeping Track: Review Underway For Linhaliq, New Uses Of Lenvima, Cimzia; New Cycle Starts For Lutathera
What's Missing In Intellipharmaceutics' Opioid Filing? FDA Panel Offers List
Opioids: Intellipharmaceutics' Pursuit Of IV-Only Deterrence Claim May Backfire
Antibiotic Pipeline Profile: Targeting Delivery To Infection Site
ASCO Upsets CDK4/6 Class: Strong Data For Lilly's Abemaciclib, But Pfizer's Ibrance Disappoints
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross
Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121677

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel